CN-122005539-A - Application of anthocyanin in preparation of product for relieving nonalcoholic fatty liver disease by regulating CCL3-FABP4 signal axis

Abstract

The invention belongs to the technical field of biological medicines and functional foods, and particularly relates to application of anthocyanin in preparation of a product for relieving nonalcoholic fatty liver disease by regulating and controlling a CCL3-FABP4 signal shaft. The invention screens and locks the core regulation signal axis CCL3-FABP4 of inflammatory-metabolic crosstalk in the process of nonalcoholic fatty liver disease through the multi-dimensional combined analysis of transcriptome, single cell transcriptome and metabonomics, and verifies through an in-vitro macrophage model and an in-vivo mouse model that anthocyanin can inhibit abnormal activation of the CCL3-FABP4 signal axis through targeting, thereby effectively improving hepatocyte lipid accumulation, pathological damage of liver tissue and lipid metabolism disorder, and can be used for preparing products for preventing and treating nonalcoholic fatty liver disease.

Inventors

• WEI JIE
• GAO JUN
• HE YUJING
• TANG XIAN
• WANG DONGXU
• LI FEI
• ZHAO MENG

Assignees

• 辽宁大学

Dates

Publication Date

20260512

Application Date

20260408

Claims (10)

1. 1. Application of anthocyanin in preparation of products for relieving nonalcoholic fatty liver disease by regulating CCL3-FABP4 signal axis.
2. 2. The use according to claim 1, wherein the product comprises a functional health food, a nutritional supplement, a non-alcoholic fatty liver disease co-intervention preparation.
3. 3. The use according to claim 1, wherein the anthocyanin reduces abnormal high expression of CCL3 and FABP4 in liver tissue during non-alcoholic fatty liver disease by targeted inhibition of abnormal activation of CCL3-FABP4 signaling axis, and achieves dual regulation of inflammatory response and lipid metabolism.
4. 4. The use according to claim 1, wherein said anthocyanins are capable of improving hepatocyte lipid accumulation, alleviating pathological damage to liver tissue, repairing liver function, regulating systemic lipid metabolism disorders, inhibiting liver inflammatory infiltrates.
5. 5. The use according to claim 1, wherein the anthocyanin is administered to the animal in an amount of from 100 to 400mg/kg body weight.
6. 6. The use according to claim 1, wherein the anthocyanins are polyphenols of natural plant origin.
7. 7. The use according to claim 6, wherein the anthocyanin is cyanidin-3-O-galactoside.
8. 8. The use according to claim 1, wherein the anthocyanin is effective to rescue lipid-induced abnormalities in fatty acid metabolism of RAW264.7 macrophages and reverse intracellular lipid accumulation.
9. 9. The use according to claim 8, wherein the anthocyanin is in a dose of 50-100 μg/mL.
10. 10. The use of claim 1, wherein the CCL3-FABP4 signaling axis is obtained by a multi-dimensional combinatorial analysis screening of transcriptomics, single cell transcriptomics, and metabolomics, and is a core regulatory signaling axis for non-alcoholic fatty liver disease inflammation-metabolic crosstalk.

Description

Application of anthocyanin in preparation of product for relieving nonalcoholic fatty liver disease by regulating CCL3-FABP4 signal axis Technical Field The invention belongs to the technical field of biological medicines and functional foods, and particularly relates to application of anthocyanin in preparation of a product for relieving nonalcoholic fatty liver disease by regulating and controlling a CCL3-FABP4 signal shaft. Background Non-alcoholic fatty liver disease (Nonalcoholic FATTY LIVER DISEASE, NAFLD) has become one of the major metabolic diseases worldwide threatening human health, and its pathological features are represented by excessive accumulation of lipid in liver cells. Although epidemiological studies have shown that ingestion of natural anthocyanin-rich plants has potential benefits for preventing metabolic diseases, systemic evidence support is still lacking at present due to the extremely complex liver microenvironment, the precise molecular targets of anthocyanins for NAFLD, and their precise regulatory pathways for the "inflammation-metabolism" cross-talk mechanism. With the development of high-throughput technology, multidimensional histology techniques offer the possibility to solve this problem. By integrating transcriptomics (RNA-seq), single cell transcriptomics (SINGLE CELL RNA-seq, scRNA-seq) and metabonomics (Metabolomics), a "gene-cell-metabolic" trans-dimensional molecular interaction network is constructed that links global gene expression regulation, cellular heterogeneity and characterization of metabolic end products. At present, the accurate positioning of the core signal axis of NAFLD by using the integrated analysis means still belongs to the field blank. Anthocyanin (Anthocyanins) is a natural polyphenol compound widely existing in dark berries, and is concerned by the medical and food science fields due to the excellent biological activity, and the application range of the anthocyanin (Anthocyanins) is gradually expanded from the original natural colorant to functional foods, nutrition enhancers and preventive medical preparations. Therefore, the anthocyanin application scheme with the accurate regulation mechanism is screened and verified based on multidimensional histology, and the method has important scientific value and practical significance for developing efficient and targeted NAFLD control products. Disclosure of Invention The invention aims at searching the anthocyanin which is highly targeted and relieves the NAFLD, screens out the inflammatory metabolism crosstalk core signal axis of the NAFLD based on the multi-dimensional histology technologies of transcriptome, single cell transcriptome and metabonomics, and uses NAFLD mouse model to verify the damage of the anthocyanin to liver tissue, the key signal axis protein expression and the like in vivo so as to evaluate the intervention effect of the anthocyanin on the NAFLD. The technical scheme adopted by the invention is as follows: application of anthocyanin in preparation of products for relieving nonalcoholic fatty liver disease by regulating CCL3-FABP4 signal axis. Further, the product comprises functional health food, nutrition enhancer and non-alcoholic fatty liver disease auxiliary intervention preparation for the application. Furthermore, in the application, abnormal activation of CCL3-FABP4 signal axis is inhibited in a targeted manner, abnormal high expression of CCL3 and FABP4 in liver tissues in the process of non-alcoholic fatty liver disease is down regulated, and dual regulation of inflammatory reaction and lipid metabolism is realized. Further, by the application, the anthocyanin can improve the lipid accumulation of liver cells, relieve pathological damage of liver tissues, repair liver functions, regulate systemic lipid metabolism disorder and inhibit liver inflammation infiltration. Further, for the above application, the anthocyanin is administered in the animal body at a dose of 100-400mg/kg body weight. Further, in the above application, the anthocyanin is a polyphenol compound of natural plant origin. Further, for the above application, the anthocyanin is cyanidin-3-O-galactoside. Further, with the application, the anthocyanin can effectively save the fatty acid metabolism abnormality of the RAW264.7 macrophage induced by high fat and reverse the lipid accumulation in cells. Preferably, 50-100 μg/mL anthocyanin can effectively save the fatty acid metabolism abnormality of RAW264.7 macrophages induced by high fat, and reverse the lipid accumulation in cells. Furthermore, in the application, the CCL3-FABP4 signal axis is obtained through multi-dimensional combined analysis and screening of transcriptomics, single cell transcriptomics and metabonomics, and is a core regulation signal axis of non-alcoholic fatty liver disease inflammation-metabolism crosstalk. The beneficial effects of the invention are as follows: 1. through a multi-dimensional combinatorial linkage integrated analys